by Portfolio Grader | December 27, 2012 5:45 pm
The ratings of four Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
BioTime (AMEX:BTX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). BioTime is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. In Portfolio Grader’s specific subcategories of Equity, Cash Flow, and Sales Growth, BTX also gets an F. As of Dec. 26, 2012, 12.1% of outstanding BioTime shares were held short. To get an in-depth look at BTX, get Portfolio Grader’s complete analysis of BTX stock.
Progenics Pharmaceuticals (NASDAQ:PGNX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock gets F’s in Earnings Momentum, Earnings Revisions, Equity, and Sales Growth. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
Oncothyreon (NASDAQ:ONTY) is having a tough week. The company’s rating falls from a D to an F. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Earnings Growth, Equity, and Cash Flow. The stock price has fallen 57.1% over the past month, worse than the 1.2% increase the Nasdaq has seen over the same period of time. For a full analysis of ONTY stock, visit Portfolio Grader.
This week, Immunogen Inc.’s (NASDAQ:IMGN) rating worsens to a D from the company’s C rating a week ago. Immunogen develops pharmaceuticals, primarily for the treatment of cancer. The stock also gets an F in Equity. For more information, get Portfolio Grader’s complete analysis of IMGN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/12/4-biotechnology-stocks-to-sell-now-btx-pgnx-onty-2/
Short URL: http://investorplace.com/?p=282915
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.